John Petros

John Petros


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in BJU International
Verified
Journal Article
Closed access
PDF file
NSN.P. Symbas
N.P. Symbas
MTM.F. Townsend
M.F. Townsend
RER. El‐Galley
R. El‐Galley
TKT.E. Keane
T.E. Keane
SGS.D. Graham
S.D. Graham
JPJohn Petros
John Petros

11 October 2018 in Cancers
Verified
Journal Article
Open access
PDF file
NSNitya V. Sharma
Nitya V. Sharma
KPKathryn L. Pellegrini
Kathryn L. Pellegrini
VOVeronique Ouellet
Veronique Ouellet
FGFelipe O. Giuste
Felipe O. Giuste
SRSelvi S Ramalingam
Selvi S Ramalingam
Carlos MorenoCarlos Moreno
Carlos Moreno
Background: Patients with locally advanced or recurrent prostate cancer typically undergo androgen deprivation therapy (ADT), but the benefits are often short-lived and the responses variable. ADT failure results in castration-resistant prostate cancer (CRPC), which inevitably leads to metastasis. We hypothesized that differences in tumor transcriptional programs may reflect differential responses to ADT and subsequent metastasis. Results: We performed whole transcriptome analysis of 20 patient-matched Pre-ADT biopsies and 20 Post-ADT prostatectomy specimens, and identified two subgroups of patients (high impact and low impact groups) that exhibited distinct transcriptional changes in response to ADT. We found that all patients lost the AR-dependent subtype (PCS2) transcriptional signatures. The high impact group maintained the more aggressive subtype (PCS1) signal, while the low impact group more resembled an AR-suppressed (PCS3) subtype. Computational analyses identified transcription factor coordinated groups (TFCGs) enriched in the high impact group network. Leveraging a large public dataset of over 800 metastatic and primary samples, we identified 33 TFCGs in common between the high impact group and metastatic lesions, including SOX4/FOXA2/GATA4, and a TFCG containing JUN, JUNB, JUND, FOS, FOSB, and FOSL1. The majority of metastatic TFCGs were subsets of larger TFCGs in the high impact group network, suggesting a refinement of critical TFCGs in prostate cancer progression. Conclusions: We have identified TFCGs associated with pronounced initial transcriptional response to ADT, aggressive signatures, and metastasis. Our findings suggest multiple new hypotheses that could lead to novel combination therapies to prevent the development of CRPC following ADT.

6 March 2009 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
Anna M. Czarnecka, MBAAnna M. Czarnecka, MBA
Anna M. Czarnecka, MBA
TKTomasz Krawczyk
Tomasz Krawczyk
MZMarek Zdrożny
Marek Zdrożny
JLJan Lubiński
Jan Lubiński
RARebecca S. Arnold
Rebecca S. Arnold
JPJohn Petros
John Petros

1 September 2015 in Bone
Verified
Journal Article
Closed access
RARebecca S. Arnold
Rebecca S. Arnold
SFStacey A. Fedewa
Stacey A. Fedewa
MGMichael Goodman
Michael Goodman
AOAdeboye O. Osunkoya
Adeboye O. Osunkoya
HKHaydn T. Kissick
Haydn T. Kissick
JPJohn Petros
John Petros

27 December 2012 in BioMed Research International
Verified
Journal Article
Open access
PDF file
RARebecca S. Arnold
Rebecca S. Arnold
QSQian Sun
Qian Sun
CSCarrie Q. Sun
Carrie Q. Sun
JRJendai C. Richards
Jendai C. Richards
SOSean O'Hearn
Sean O'Hearn
JPJohn Petros
John Petros
Mitochondrial DNA (mtDNA) mutations have been found in many cancers but the physiological derangements caused by such mutations have remained elusive. Prostate cancer is associated with both inherited and somatic mutations in the cytochrome c oxidase (COI) gene. We present a prostate cancer patient-derived rare heteroplasmic mutation of this gene, part of mitochondrial respiratory complex IV. Functional studies indicate that this mutation leads to the simultaneous decrease in cytochrome oxidation, increase in reactive oxygen, and increased reactive nitrogen. These data suggest that mitochondrial DNA mutations resulting in increased reactive oxygen and reactive nitrogen generation may be involved in prostate cancer biology.

22 March 2019 in Cancer Biology & Therapy
Verified
Journal Article
Open access
CSCarrie Q. Sun
Carrie Q. Sun
RARebecca S. Arnold
Rebecca S. Arnold
CHChia-Ling Hsieh
Chia-Ling Hsieh
JDJulia R. Dorin
Julia R. Dorin
FLFei Lian
Fei Lian
JPJohn Petros
John Petros
Human beta-defensin-1 (hBD-1) is one of a number of small cationic host-defense peptides. Besides its well-known broad-spectrum antimicrobial function, hBD-1 has recently been identified as a chromosome 8p tumor-suppressor gene. The role of hBD-1 in modulating the host immune response to oncogenesis, associated with cell signaling and potential therapeutic applications, has become increasingly appreciated over time. In this study, multiple approaches were used to illustrate hBD-1 anti-tumor activities. Results demonstrate that hBD-1 peptide alters human epidermal growth factor receptor 2 (HER2) signal transduction and represses retroviral-mediated transgene expression in cancer cells. Loss of orthologous murine defense-1 (mBD1) in mice enhances nickel sulfate-induced leiomyosarcoma and causes mouse kidney cells to exhibit increased susceptibility to HPV-16 E6/7-induced neoplastic transformation. Furthermore, for the first time, a novel function of the urine-derived hBD-1 peptide was discovered to suppress bladder cancer growth and this may lead to future applications in the treatment of malignancy.